SANTA CLARA, Calif., May 28, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, announced today that its board of directors has adopted bitcoin as its primary treasury reserve asset. In addition, Semler Scientific announced that it has purchased 581 bitcoins for an aggregate amount of $40 million, inclusive of fees and expenses. "Our bitcoin treasury strategy and purchase of b ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-36305 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (State ...

Financial Data and Key Metrics - Total revenues in Q1 2024 were $15.9 million, a decrease of 13% compared to Q1 2023 [5] - Fixed fee revenues were $7.1 million, a decrease of 24% year-over-year [5] - Variable fee revenues were $8 million, a decrease of 6% year-over-year [5] - Equipment and other revenues were $0.8 million, an increase of 140% year-over-year [33] - Operating expenses in Q1 2024 were $8.9 million, a decrease of 25% year-over-year, representing 56% of revenues compared to 66% in 2023 [6] - Pretax net income was $7.8 million compared to $6.6 million in the prior year [7] - Net income was $6.1 million or $0.88 per basic share and $0.78 per fully diluted share, compared to $5 million or $0.74 per basic share and $0.63 per fully diluted share in Q1 2023 [7] - Cash balance at March 31, 2024, was a record high of $62.9 million [7] Business Line Data and Key Metrics - The company's revenues are driven by sales of QuantaFlo for testing peripheral arterial disease (PAD) [5] - The three largest customers, including their related affiliates, comprised 45%, 25%, and 11% of quarterly revenue [6] - The company is pursuing an additional 510(k) clearance from the FDA for QuantaFlo to broaden its utility for a wider array of cardiovascular diseases, with anticipated clearance in the second half of 2024 [8][40] Market Data and Key Metrics - The Centers for Medicare and Medicaid Services (CMS) announced the three-year phase-in of the removal of the HCC code relating to PAD without complications from the Medicare Advantage risk adjustment model, with 2024 being the first year of the phase-in [11] - The company expects revenues in 2024 to follow a similar cadence to 2023, with H1 more heavily weighted than H2 [11][44] Company Strategy and Industry Competition - The company is focused on expanding its customer base for PAD and exploring inorganic growth initiatives to diversify its product portfolio [17][49] - The company is committed to research and development to enhance existing products and data services, with a long-term vision of extending its reach to additional cardiovascular applications [36] - The company aims to establish QuantaFlo as the standard of care for PAD diagnosis and diversify its customer base by adding new medical centers and expanding within value-based care providers and the VA system [35] Management Commentary on Operating Environment and Future Outlook - The company achieved year-over-year earnings growth despite a regulatory-driven revenue decline from its PAD product [2] - The company anticipates a slight uptick in expenses as it prepares for the next phase of launching QuantaFlo with expanded use [12] - The company is encouraged by the continued testing for PAD, given the importance of early diagnosis and treatment [11] - The company believes its technology can play a central role in delivering healthier outcomes for patients and substantial economic value to customers [15] Other Important Information - The company has a $20 million share buyback authorization, with $5 million already repurchased and $15 million remaining [45] Q&A Session Summary Question: Timing and process for receiving the 510(k) clearance - The company anticipates receiving clearance in the second half of 2024 and will start marketing the expanded use of QuantaFlo to existing customers upon approval [40][50] Question: Current demand environment and potential customer loss - The company has seen continued testing for PAD but also some cleanup of underutilized units. The clinical value of testing remains the same, and the company has a robust pipeline for growth [23][24] Question: Potential uses of cash for inorganic growth opportunities - The company is exploring inorganic growth initiatives, including strategic partnerships and acquisitions, to diversify its product portfolio [17][51] Question: Revenue cadence for 2024 - The company expects revenues to follow a similar cadence to 2023, with H1 more heavily weighted than H2 [44] Question: Specific conditions QuantaFlo might identify with the 510(k) clearance - The expanded use of QuantaFlo will focus on heart dysfunction, with specific wording to be released upon FDA clearance [41]

Exhibit 99.1 Semler Scientific® Reports First Quarter 2024 Financial Results 2024 Q1 highlights compared to the corresponding period of 2023: ● First quarter revenues were $15.9 million, a decrease of 13% ● First quarter net income was $6.1 million, an increase of 22% ● Cash, cash equivalents and restricted cash balance increased to $62.9 million Santa Clara, CA – May 7, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission file number: 001-36305 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (State or other ju ...

Semler Scientific, Inc. (NASDAQ:SMLR) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Doug Murphy-Chutorian - Chief Executive Officer Renae Cormier - Chief Financial Officer Jennifer Oliva Herrington - Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to the Semler Scientific 2023 Fourth Quarter Financial Results Conference Call. All participants will be in a listen-only mode [Operator Instruct ...

Exhibit 99.1 Semler Scientific Reports Fourth Quarter and Full Year 2023 Financial Results 2023 Q4 and full year highlights compared to the corresponding period of 2022: Santa Clara, CA – March 5, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023. "We are pleased to report ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission File Number: 001-36305 SEMLER SCIENTIFIC, INC. FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ (Exact name of registrant as specified in its charter) Delaware 26-1367393 (St ...

Semler Scientific, Inc. (NASDAQ:SMLR) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Doug Murphy-Chutorian – Chief Executive Officer Renae Cormier – Chief Financial Officer Jennifer Oliva Herrington – Chief Operating Officer Conference Call Participants Aaron Wukmir – Lake Street Capital Markets Herbert Semler – Semler Health Operator Good afternoon, and welcome to the Semler Scientific 2023 Third Quarter Financial Results Conference Call. All participants will be in a lis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-36305 SEMLER SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 26-1367393 (State o ...